Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20541830 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29688162 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29688002 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29831258 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL23044599 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29831260 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29687742 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL30475705 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL24059359 | 0.96 | EIF2AK3 (0.92) | EIF2AK3EIF2S1 | |
| Fumaric Acid SCHEMBL30828818 | 0.95 | EIF2AK3 (0.90) | EIF2AK3EIF2S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039675-B1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | LILLY CO ELI (US) | 2024-06-12 | — | — | EP | claimed |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | claimed |
| EP-4039675-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | Eli Lilly and Company (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114585606-A | PERK inhibiting compounds | 希伯塞尔股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-12473296-B2 | Perk inhibiting compounds | HIBERCELL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2024077099-A1 | PERK INHIBITOR HC-5404 IN COMBINATION WITH ANTI-PD-1 ANTIBODY AND/OR AN ANTIANGIOGENETIC AGENT FOR USE IN THE TREATMENT OF CANCER | HIBERCELL, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-3775171-B1 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2023-11-23 | — | — | US | disclosed |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | ELI LILLY AND COMPANY (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | ELI LILLY AND COMPANY (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-4021893-A1 | PERK INHIBITING COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114585606-A | PERK inhibiting compounds | 希伯塞尔股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3612519-B1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | LILLY CO ELI (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210121527-A1 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-04-29 | — | — | US | disclosed |
| US-20210114985-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | ELI LILLY AND COMPANY | 2021-04-22 | — | — | US | disclosed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121527-A1 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | BMP4, BMP2K, BMP2 | EIF2AK3 526/4885EIF2S1 202/4885 |
| US-20210114985-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | EP300, PC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EIF2AK3 987/4885EIF2S1 2387/4885 |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | ATF4, EEF2K, ERN1 | EIF2AK3 75/4885EIF2S1 380/4885 |
| US-11655214-B2 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds for the treatment of pancreatic cancer | PNLIP, RNASE1, AMY2A | EIF2AK3 1111/4885EIF2S1 2270/4885 |
| US-20230373922-A1 | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS FOR THE TREATMENT OF PANCREATIC CANCER | PNLIP, RNASE1, AMY2A | EIF2AK3 1410/4885EIF2S1 3050/4885 |
| US-12473296-B2 | Perk inhibiting compounds | MAPK1, ERN1, MAP3K20 | EIF2AK3 69/4885EIF2S1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.